Novartis ends mid-stage trial for Fabhalta in lupus nephritis
Summary
Pharmaceutical company Novartis has decided to stop its mid-stage clinical study evaluating the drug Fabhalta for the treatment of lupus nephritis. The trial discontinuation marks a significant change in the development program for this specific medical indication.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.